EMD Serono and Pfizer to scrap Phase III Head and Neck cancer trial
EMD Serono, the biopharmaceutical business of Merck, and Pfizer have decided to terminate the Phase III JAVELIN Head and Neck 100 study as it established that avelumab (Bavencio)
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More XEMD Serono, the biopharmaceutical business of Merck, and Pfizer have decided to terminate the Phase III JAVELIN Head and Neck 100 study as it established that avelumab (Bavencio)
Biotechnology firm Immutep has received second investigational new drug (IND) approval from the US Food and Drug Administration (FDA) for eftilagimod alpha (efti or IMP321), which is designed
Biopharmaceutical company Harbour BioMed has entered into a partnership with Mount Sinai Health System of New York City to develop novel antibodies that treat and prevent oncology and
The US Food and Drug Administration (FDA) has issued an emergency use authorisation (EUA) of a diagnostic test for the 2019 novel coronavirus. Created by the Centers for
Drug development accelerator BioMotiv has partnered with Bristol-Myers Squibb to launch a new biotechnology company, Anteros Pharmaceuticals. The new firm will be involved in developing a new class
UK-based pharmaceutical firm GlaxoSmithKline (GSK) has joined forces with the Coalition for Epidemic Preparedness Innovations (CEPI) to develop a vaccine for the novel Coronavirus (2019-nCoV). Coronaviruses are a
The UK government has announced £20m in funding to develop a new vaccine to fight the deadly Novel Coronavirus (2019-nCoV) outbreak in China, also known as the Wuhan